{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:17:15Z","timestamp":1782123435243,"version":"3.54.5"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jsbmb.2024.106623","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:09:23Z","timestamp":1726762163000},"page":"106623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Are androgen receptor agonists a treatment option in bladder cancer?"],"prefix":"10.1016","volume":"245","author":[{"given":"Michael L.","family":"De Ieso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Faris","family":"Aldoghachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne D.","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jsbmb.2024.106623_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106623_bib2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40273-023-01273-8","article-title":"Cost-effectiveness and economic impact of bladder cancer management: an updated review of the literature","volume":"41","author":"Joyce","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jsbmb.2024.106623_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J. Urol."},{"issue":"4","key":"10.1016\/j.jsbmb.2024.106623_bib4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur. Urol. Focus"},{"issue":"10061","key":"10.1016\/j.jsbmb.2024.106623_bib5","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jsbmb.2024.106623_bib6","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur. Urol."},{"issue":"19","key":"10.1016\/j.jsbmb.2024.106623_bib7","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106623_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib11","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med. Sci."},{"issue":"20","key":"10.1016\/j.jsbmb.2024.106623_bib12","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/jnci\/82.20.1636","article-title":"Unexplained excess risk of bladder cancer in men","volume":"82","author":"Hartge","year":"1990","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106623_bib14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MOU.0b013e32833c7a9b","article-title":"Female bladder cancer: incidence, treatment, and outcome","volume":"20","author":"Scosyrev","year":"2010","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.jsbmb.2024.106623_bib15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00345-012-0996-9","article-title":"Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder","volume":"31","author":"Kluth","year":"2013","journal-title":"World J. Urol."},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106623_bib16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.21037\/tau.2016.03.22","article-title":"Female with bladder cancer: what and why is there a difference?","volume":"5","author":"Marks","year":"2016","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.jsbmb.2024.106623_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.diff.2018.08.004","article-title":"Development of the human bladder and ureterovesical junction","volume":"103","author":"Liaw","year":"2018","journal-title":"Differentiation"},{"issue":"6","key":"10.1016\/j.jsbmb.2024.106623_bib18","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.juro.2014.01.012","article-title":"Testosterone changes bladder and kidney structure in juvenile male rats","volume":"191","author":"Shortliffe","year":"2014","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.jsbmb.2024.106623_bib19","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.urology.2009.08.016","article-title":"The effect of testosterone replacement therapy on bladder functions and histology in orchiectomized mature male rats","volume":"75","author":"Tek","year":"2010","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1620\/tjem.226.121","article-title":"Androgen deprivation induces bladder histological abnormalities and dysfunction via TGF-\u03b2 in orchiectomized mature rats","volume":"226","author":"Zhang","year":"2012","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.jsbmb.2024.106623_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11010-007-9415-8","article-title":"Effect of castration on male rabbit lower urinary tract tissue enzymes","volume":"301","author":"Juan","year":"2007","journal-title":"Mol. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.jsbmb.2024.106623_bib22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1073\/pnas.0408925102","article-title":"Mutation of the androgen receptor causes oncogenic transformation of the prostate","volume":"102","author":"Han","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen-independent prostate cancer","volume":"1","author":"Feldman","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2024.106623_bib24","first-page":"1","article-title":"The androgen receptor in bladder cancer","author":"Chen","year":"2023","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"10.1016\/j.jsbmb.2024.106623_bib25","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/biom11040594","article-title":"The role of androgens and androgen receptor in human bladder cancer","volume":"11","author":"Mart\u00ednez-Rojo","year":"2021","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106623_bib26","doi-asserted-by":"crossref","first-page":"R265","DOI":"10.1530\/ERC-15-0209","article-title":"The emerging role of the androgen receptor in bladder cancer","volume":"22","author":"Lombard","year":"2015","journal-title":"Endocr.-Relat. Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/BLC-160052","article-title":"Effects of androgen and estrogen receptor signaling pathways on bladder cancer initiation and progression","volume":"2","author":"Godoy","year":"2016","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cancers9020020","article-title":"Androgen receptor signaling in bladder cancer","volume":"9","author":"Li","year":"2017","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106623_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/14728222.2017.1280468","article-title":"Androgen receptor activation: a prospective therapeutic target for bladder cancer?","volume":"21","author":"Mizushima","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106623_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ajur.2020.05.011","article-title":"Androgen receptor in bladder cancer: a promising therapeutic target","volume":"7","author":"Tripathi","year":"2020","journal-title":"Asian J. Urol."},{"issue":"4","key":"10.1016\/j.jsbmb.2024.106623_bib31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/cancers16040746","article-title":"Roles of androgen receptor signaling in urothelial carcinoma","volume":"16","author":"Sundi","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.urology.2004.03.025","article-title":"Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer","volume":"64","author":"Boorjian","year":"2004","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0303-7207(96)03819-1","article-title":"A and B forms of the androgen receptor are expressed in a variety of human tissues","volume":"120","author":"Wilson","year":"1996","journal-title":"Mol. Cell. Endocrinol."},{"issue":"12","key":"10.1016\/j.jsbmb.2024.106623_bib34","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1464-410X.2008.07521.x","article-title":"Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study","volume":"101","author":"Koritsiadis","year":"2008","journal-title":"BJU Int."},{"key":"10.1016\/j.jsbmb.2024.106623_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00210-017-1355-6","article-title":"Effect of short-term androgen deficiency on bladder contractility and urothelial mediator release","volume":"390","author":"Bravo","year":"2017","journal-title":"Naunyn-Schmiede's\u00a0Arch. Pharm."},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106623_bib36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/jnci\/djk113","article-title":"Promotion of bladder cancer development and progression by androgen receptor signals","volume":"99","author":"Miyamoto","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2024.106623_bib37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.omtn.2021.01.028","article-title":"miR-224-5p-enriched exosomes promote tumorigenesis by directly targeting androgen receptor in non-small cell lung cancer","volume":"23","author":"Zhou","year":"2021","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"10.1016\/j.jsbmb.2024.106623_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbrc.2021.02.120","article-title":"Loss of androgen receptor promotes HCC invasion and metastasis via activating circ-LNPEP\/miR-532-3p\/RAB9A signal under hypoxia","volume":"557","author":"Ouyang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106623_bib39","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.7150\/jca.49200","article-title":"Androgen receptor (AR) decreases HCC cells migration and invasion via miR-325\/ACP5 signaling","volume":"12","author":"Ouyang","year":"2021","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41591-020-01168-7","article-title":"The androgen receptor is a tumor suppressor in estrogen receptor\u2013positive breast cancer","volume":"27","author":"Hickey","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106623_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(24)00004-4","volume":"25","author":"Palmieri","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(17)30906-3","article-title":"Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study","volume":"19","author":"Teply","year":"2018","journal-title":"Lancet Oncol."},{"issue":"269","key":"10.1016\/j.jsbmb.2024.106623_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"13","key":"10.1016\/j.jsbmb.2024.106623_bib44","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/pros.23209","article-title":"Bipolar androgen therapy for men with androgen ablation naive prostate cancer: results from the phase II BATMAN study","volume":"76","author":"Schweizer","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2024.106623_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5064","article-title":"Overall survival (OS) and biomarker results from combat: a phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC)","author":"Markowski","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2024.106623_bib46","first-page":"22","article-title":"Supraphysiological androgens promote the tumor suppressive activity of the androgen receptor through cMYC repression and recruitment of the DREAM complex","author":"Nyquist","year":"2023","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jsbmb.2024.106623_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146777","article-title":"Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth","volume":"131","author":"Nyquist","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"19","key":"10.1016\/j.jsbmb.2024.106623_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129715","article-title":"Molecular determinants of response to high-dose androgen therapy in prostate cancer","volume":"4","author":"Nyquist","year":"2019","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106623_bib49","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/2767-9764.CRC-21-0139","article-title":"Potent stimulation of the androgen receptor instigates a viral mimicry response in prostate cancer","volume":"2","author":"Alizadeh-Ghodsi","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106623_bib50","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1248\/bpb.b12-00885","article-title":"Mechanism of the tissue-specific action of the selective androgen receptor modulator S-101479","volume":"36","author":"Furuya","year":"2013","journal-title":"Biol. Pharm. Bull."},{"issue":"15","key":"10.1016\/j.jsbmb.2024.106623_bib51","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-09-0452","article-title":"Androgen receptor inhibits estrogen receptor-\u03b1 activity and is prognostic in breast cancer","volume":"69","author":"Peters","year":"2009","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.jsbmb.2024.106623_bib52","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1210\/me.2012-1107","article-title":"Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?","volume":"26","author":"Hickey","year":"2012","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106623_bib53","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/MOU.0000000000000092","article-title":"Sex steroids and gender differences in nonmuscle invasive bladder cancer","volume":"24","author":"Lucca","year":"2014","journal-title":"Curr. Opin. Urol."},{"issue":"4","key":"10.1016\/j.jsbmb.2024.106623_bib54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.genm.2008.11.002","article-title":"Gender-specific differences in bladder cancer: a retrospective analysis","volume":"5","author":"Horstmann","year":"2008","journal-title":"Gend. Med."},{"issue":"6","key":"10.1016\/j.jsbmb.2024.106623_bib55","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.euf.2017.08.007","article-title":"Gender-specific differences in recurrence of non\u2013muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"4","author":"Uhlig","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.jsbmb.2024.106623_bib56","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2019.12.008","article-title":"Pan-cancer immunogenomic analyses reveal sex disparity in the efficacy of cancer immunotherapy","volume":"126","author":"Wang","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib57","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1038\/s41598-021-84787-5","article-title":"Pancancer survival analysis of cancer hallmark genes","volume":"11","author":"Nagy","year":"2021","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106623_bib58","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1210\/endo.140.7.6769","article-title":"Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells","volume":"140","author":"Yeap","year":"1999","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106623_bib59","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3892\/mco.2017.1389","article-title":"Expression and clinical significance of androgen receptor in bladder cancer: a meta\u2011analysis","volume":"7","author":"Chen","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2024.106623_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lfs.2017.09.029","article-title":"Expression of AR, 5alphaR1 and 5alphaR2 in bladder urothelial carcinoma and relationship to clinicopathological factors","volume":"190","author":"Hata","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.jsbmb.2024.106623_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijso.2023.100645","article-title":"Expression of androgen receptor in bladder cancer: a tertiary care center study","volume":"56","author":"Obeidat","year":"2023","journal-title":"Int. J. Surg. Open"},{"issue":"8","key":"10.1016\/j.jsbmb.2024.106623_bib62","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-18-3121","article-title":"Clinical and genomic implications of luminal and basal subtypes across carcinomas","volume":"25","author":"Zhao","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13059-023-03161-y","article-title":"The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer","volume":"25","author":"Hosseinzadeh","year":"2024","journal-title":"Genome Biol."},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ccr.2008.01.011","article-title":"GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model","volume":"13","author":"Kouros-Mehr","year":"2008","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib65","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncb1530","article-title":"Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation","volume":"9","author":"Asselin-Labat","year":"2007","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib66","doi-asserted-by":"crossref","first-page":"38531","DOI":"10.1038\/srep38531","article-title":"FOXA1, GATA3 and PPAR\u0263 cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines","volume":"6","author":"Warrick","year":"2016","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.jsbmb.2024.106623_bib67","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.jsbmb.2024.106623_bib68","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-20-3095","article-title":"Androgen receptor regulates CD44 expression in bladder cancer","volume":"81","author":"Sottnik","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106623_bib69","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ccell.2016.08.002","article-title":"An osteopontin\/CD44 axis in RhoGDI2-mediated metastasis suppression","volume":"30","author":"Ahmed","year":"2016","journal-title":"Cancer Cell"},{"issue":"11-12","key":"10.1016\/j.jsbmb.2024.106623_bib70","doi-asserted-by":"crossref","first-page":"320","DOI":"10.18632\/oncoscience.335","article-title":"CD44: a metastasis driver and therapeutic target","volume":"3","author":"Sottnik","year":"2016","journal-title":"Oncoscience"},{"issue":"6","key":"10.1016\/j.jsbmb.2024.106623_bib71","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/cancers16061195","article-title":"CD44 in bladder cancer","volume":"16","author":"Duex","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106623_bib72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/(SICI)1097-0045(199603)28:3<153::AID-PROS2>3.0.CO;2-G","article-title":"Expression of CD44 isoforms in human prostate tumor cell lines","volume":"28","author":"Stevens","year":"1996","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib73","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1002\/jcb.27573","article-title":"Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2","volume":"120","author":"Srinivasan","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"7915","key":"10.1016\/j.jsbmb.2024.106623_bib74","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jsbmb.2024.106623_bib75","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/s41417-022-00506-w","article-title":"Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2\/circ_0001005\/PD-L1 signaling","volume":"29","author":"Liu","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib76","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/j.clgc.2017.09.016","article-title":"Association of androgen receptor expression on tumor cells and PD-L1 expression in muscle-invasive and metastatic urothelial carcinoma: insights for clinical research","volume":"16","author":"Necchi","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106623_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2023.100148","article-title":"Androgen receptor transcriptionally inhibits programmed death ligand-1 expression and influences immune escape in bladder cancer","volume":"103","author":"Sun","year":"2023","journal-title":"Lab. Investig."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib78","doi-asserted-by":"crossref","first-page":"9657","DOI":"10.1038\/s41598-023-33915-4","article-title":"CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis","volume":"13","author":"Liu","year":"2023","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106623_bib79","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/0008-5472.CAN-19-1108","article-title":"CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers","volume":"80","author":"Kong","year":"2020","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.jsbmb.2024.106623_bib80","doi-asserted-by":"crossref","first-page":"8709","DOI":"10.18632\/oncotarget.3325","article-title":"Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer","volume":"6","author":"Cho","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106623_bib81","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1083\/jcb.200108159","article-title":"Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway","volume":"155","author":"Okamoto","year":"2001","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106623_bib82","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1038\/s41598-023-34154-3","article-title":"The prognostic value and immunological role of CD44 in pan-cancer study","volume":"13","author":"Chen","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jsbmb.2024.106623_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102142","article-title":"Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: what to expect in the near future","volume":"93","author":"Rey-C\u00e1rdenas","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.jsbmb.2024.106623_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134346","article-title":"Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy","volume":"10","author":"Pan","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jsbmb.2024.106623_bib86","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.trsl.2015.02.001","article-title":"Patient-derived bladder cancer xenografts: a systematic review","volume":"166","author":"Bernardo","year":"2015","journal-title":"Transl. Res."},{"issue":"10","key":"10.1016\/j.jsbmb.2024.106623_bib87","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1073\/pnas.1803595116","article-title":"Mouse and human urothelial cancer organoids: a tool for bladder cancer research","volume":"116","author":"Mullenders","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106623_bib88","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.jsbmb.2024.106623_bib89","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/1878-0261.12354","article-title":"A patient-derived explant (PDE) model of hormone-dependent cancer","volume":"12","author":"Centenera","year":"2018","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.jsbmb.2024.106623_bib90","doi-asserted-by":"crossref","first-page":"2001594","DOI":"10.1002\/adhm.202001594","article-title":"Patient-derived prostate cancer explants: a clinically relevant model to assess siRNA-based nanomedicines","volume":"10","author":"Tieu","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106623_bib91","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3390\/cancers14071708","article-title":"Harnessing the heterogeneity of prostate cancer for target discovery using patient-derived explants","volume":"14","author":"Centenera","year":"2022","journal-title":"Cancers"},{"issue":"7560","key":"10.1016\/j.jsbmb.2024.106623_bib92","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076024001717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076024001717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T22:05:55Z","timestamp":1732831555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076024001717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":92,"alternative-id":["S0960076024001717"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2024.106623","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are androgen receptor agonists a treatment option in bladder cancer?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2024.106623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106623"}}